News

Innovative acne treatments emerge, including sponge-derived therapies and microbiome strategies, promising a brighter future for patients.

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

This review of the latest vitiligo studies includes insights on the efficacy of ritlecitinib, the risk of herpes zoster, oxidative stress in red blood cells for this patient population, and more.

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Karen McGuire, PhD, discusses TolaSure, a groundbreaking therapy targeting epidermolysis bullosa simplex, focusing on cellular repair and blister reduction.

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Explore the potential of glucagon-like peptide-1 (GLP-1) therapies in dermatology, including inflammatory skin diseases such as psoriasis and hidradenitis suppurativa, to improve patient outcomes.

Jennelle Daly, MPAS, PA-C, reveals essential winter sunscreen insights, emphasizing UVA risks and patient education for effective photoprotection against melanoma.

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Obagi and Alpha Aesthetics Partners will collaborate on the ALOHA Program, enhancing real-world evidence for the innovative saypha MagIQ hyaluronic acid filler.

Christopher Bunick, MD, PhD, led a vital discussion on innovative vitiligo treatments, emphasizing combination therapies and psychosocial support for effective management.

Discover essential career insights for early-career NP/PAs in dermatology, focusing on skill mastery, mentorship, and professional growth strategies.

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

Discover how a new topical cream effectively improves skin volume and elasticity in patients experiencing rapid weight loss.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 delgocitinib in lichen sclerosus, amlitelimab's every-12-week dosing in AD, Galderma's phase 3 aesthetics data, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the transformative role of AI in dermatology with Nawar Shara, PhD, focusing on personalized skin care and patient safety.

Galderma showcased relabotulinumtoxinA and abobotulinumtoxinA at TOXINS 2026, highlighting innovative injectables with sustained results and high patient satisfaction.

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

The survey revealed significant concerns about topical steroid use in chronic skin diseases, highlighting the need for proactive, long-term treatment strategies.

Tina Alster, MD; Daniel Schlessinger, MD; and Mary Lupo, MD, shared their insights on upcoming aesthetic innovations at the American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Explore the latest advancements in dermatology for 2026, focusing on clinical innovation, emerging research, and practical insights for improved patient care.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of January.

Firas G. Hougeir, MD, and clinician attendees discussed how to use real-world patient scenarios to determine optimal timing for biologic initiation for patients with moderate to severe HS.

Switching from dupilumab to upadacitinib significantly improves skin clearance and itch in patients with moderate to severe atopic dermatitis (AD).

Atopia Therapeutics advances ATP-R13 as a promising oral therapy for atopic dermatitis (AD), showing significant efficacy and enhanced patent protection.

The 2025 Inflammatory Skin Disease Summit (ISDS) unveils innovative therapies and immune profiling strategies, transforming the landscape of dermatological care.